AhamedS.R., BroomanP.J.C., ShaletS.M.: Treatment of advanced prostatic cancer with LH-RH analogue ICI-118630: clinical response and hormonal mechanisms. Lancet, 2; 415–419 (1983).
2.
BoccardoF., DecensiA.U., Di CristinaL., GuarneriD.: Ruolo della chemioterapia nel trattamento del carcinoma prostatico. Acta Urol. Ital., 2; Suppl. 1, 29–41 (1988).
3.
GlashanR.W., RobinsonM.R.G.: Cardiovascular complications in the treatment of prostatic carcinoma. Brit. J. Urol., 53; 624–631 (1981).
4.
HugginsC., HodgesC.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1; 293–297 (1941).
5.
HugginsC., StevensR.E.jr., HodgesC.V.: Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43; 209–223 (1941).
6.
HugginsC., ScottW.W., HodgesC.V.: Studies on prostatic cancer. III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J. Urol., 46; 997–1006 (1941).
7.
IsaacsJ.T., KyprianouN.: Biological basis for combined chemo-hormonal therapy for prostatic cancer. In: New Trends in Diagnosis and Treatment of Prostatic Cancer. Proceedings of the First International Symposium on Advances in Urologic Oncology. GiulianiL., BoccardoF., SantiL., PescatoreD. (eds.). Acta Medica Edizioni e Congressi, 241–55, Roma 1987.
SlackN.H., BradyM.F., MurphyG.P.: A reexamination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer, 54; 564–574 (1984).